Study Findings
A new drug, called orforglipron, has shown promising results in a year-long study involving 376 participants in the United States. These individuals had previously lost weight using injectable obesity medications. The research, published in Nature Medicine, found that patients who switched to the tablet after stopping injections were able to maintain significantly more weight loss compared to those given a placebo.
The trial, funded by manufacturer Eli Lilly, revealed that participants taking orforglipron retained more than 70% of their earlier weight loss, while those in the placebo group retained roughly 38% to 50%. Researchers believe these findings address a significant challenge associated with GLP-1 drugs, where many patients experience weight regain after discontinuing treatment.
Alternative to Injections
Orforglipron functions by mimicking hormones that suppress appetite and promote a feeling of fullness for extended periods, similar to injectable weight-loss medications. Experts suggest that the tablet form may be more appealing to patients who are hesitant to use regular injections.
Dr Marie Spreckley, a weight management researcher at the University of Cambridge who was not involved in the study, commented: “We still do not know how durable these effects will be over longer periods of time.” She added that this study highlights the growing understanding that obesity is a chronic, relapsing condition that often requires continuous treatment and support.
During the trial, side effects such as nausea, constipation, and diarrhoea were reported, though most symptoms were described as mild.
Wider Impact
Dr Simon Cork of Anglia Ruskin University referred to the findings as “a really important study” because it addresses the issue of weight rebound after stopping GLP-1 injections. He also noted that improvements in blood pressure, cholesterol, and blood sugar levels appeared to persist in patients taking the oral medication.
Health experts emphasize that maintaining these benefits long-term could help reduce risks associated with obesity, including heart disease. The drug is already available in the US and may eventually be launched in the UK, although pricing details for Britain have not yet been announced.
